Trial Search Results

A Study of an Investigational V212/Heat-Treated VZV Vaccine in Immunocompromised Adults (V212-002)(COMPLETED)

The proposed indication for the investigational heat-treated varicella-zoster virus (VZV) vaccine is the prevention of herpes zoster (HZ) and HZ-related complications in immunocompromised individuals.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Merck Sharp & Dohme Corp.

Stanford Investigator(s):

Intervention(s):

  • Biological: Comparator: V212
  • Biological: Comparator: Placebo

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   - Men and women > or = to 18 years of age who are scheduled to receive an autologous or
   allogeneic hematopoietic cell transplant within 60 days of enrollment

   - HIV-infected patients with a baseline CD4 cell count < or = to 200 cells/mm^3

   - Patients with hematologic malignancies; or patients who are receiving chemotherapy for
   breast, colorectal, lung, or ovarian malignancies

Exclusion Criteria:

   - History of allergy to any vaccine component

   - Prior history of HZ

   - Prior history of receipt of any varicella or zoster vaccine

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Dora Ho
6507362442
Not Recruiting